EQT Life Sciences leads USD 75 million Series B in Atalanta Therapeutics, a biotech firm developing treatments for epilepsy and Huntington's disease.
Saved in:
| Title: | EQT Life Sciences leads USD 75 million Series B in Atalanta Therapeutics, a biotech firm developing treatments for epilepsy and Huntington's disease. |
|---|---|
| Source: | Pharma Business Week. 2/14/2025, p861-861. 1p. |
| Database: | Business Source Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 15436675 |
|---|
